T1	Participants 252 343	multi-center, phase II chemoprevention trial targeting men at high risk for prostate cancer
T2	Participants 1211 1328	Ninety-four (94) subjects consented to participate with 34% of these subjects (n=74) meeting all eligibility criteria
T3	Participants 868 901	3547 individuals were prescreened
T4	Participants 384 411	multi-center clinical trial
